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Cluster of Parvovirus Infection Among Hospital 
Staff Working in Coronary Care Units
Yee-Chun Chen,1,2,3* Mao-Yuan Chen,1,3 Chun-Yi Lu,4 Hsin-Hsin Chang,2
Chien-Ching Hung,1,2 Mei-Yu Chen,5 Mei-Ling Chen2,6
Background: Parvovirus B19 is associated with erythema infectiosum in children or arthralgia and arthritis
in adults. The virus is relatively conserved and nucleotide identity is expected in viruses that are epidemio-
logically related. Here, we describe the first cluster of parvovirus infection among hospital staff documented
in Taiwan.
Methods: Active surveillance was conducted in coronary care units (CCUs) at a 2200-bed teaching hospital
for 1 month in 2007. A case defined clinically as occurring in a patient or staff in CCUs with new onset of
fever or rash. Serum was tested for parvovirus B19 IgM and IgG by immunoblotting and DNA by nested
polymerase chain reaction. When viremia was detected, nucleotide sequences were analyzed and com-
pared with those of two clinical isolates. The attack rate was defined as the cumulative incidence of acute
infection in CCU staff and patients during the study period.
Results: Among 57 staff and 15 patients, five nurses met the clinical case definition. Three had acute infec-
tion as demonstrated by viral DNA and IgM. The attack rate was 5.3% for the staff and zero for patients.
Seroprevalence rate was lower in staff than in patients (26.3% vs. 53.3%). The isolates collected from three
cases were highly similar to a community isolate, and they varied with each other by 2–6 nucleotides. The
isolate collected from a nurse was identical to that from her friend 3 weeks apart and was concordant with
mutual transmission. A sequence with 45 nucleotide variations was identified from a staff member with
chronic infection who was negative for IgM and had only weak IgG anti-VP1 reaction with immunoblot-
ting. We did not find any patient as the source of infection.
Conclusion: We identified a cluster of parvovirus infection that was caused by three circulating strains
which did not support the hypothesis of transmission of a single strain in CCUs.
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Parvovirus B19 is associated with erythema infec-
tiosum or fifth disease (slapped cheek syndrome)
in children, arthralgia and arthritis in adults, 
hydrops fetalis, second-trimester abortion, and
transient aplastic crises in patients with hemo-
globinopathy, and chronic anemia or lethal cytope-
nia in immunocompromised patients.15 Parvovirus
B19 infection occurs worldwide; however, epi-
demiological data in Taiwan are limited.6,7
Local epidemics are not unusual and occur in
the spring every 3–4 years in temperate coun-
tries.1,2 The virus is transmitted through respira-
tory droplets, fomites and blood products, and
vertically from mother to fetus.4,5 The incubation
period of the infection ranges from 4 to 14 days.
The transmission rate is about 50% for those
who live with infected persons and 20–30% for
susceptible teachers and day care workers who
are exposed to infected children.2,5
Parvovirus B19 virus is a small, single-stranded
DNA virus that is relatively conserved, and nu-
cleotide identity is expected in viruses that are
epidemiologically related.2,8 The lack of a lipid
envelope makes it resistant to physical inactivation
with heat or detergents.1 Nosocomial transmission
has been documented,8,9 although outbreaks in
hospitals or virus transmission to hospital staff
from infected patients appears to be rare.4,5,10 Here,
we describe the first documented cluster of par-
vovirus infection among hospital staff at a teach-
ing hospital in Taiwan.
Methods
Hospital setting and study units
National Taiwan University Hospital is a 2,200-bed
major teaching hospital in Taiwan that provides
both primary and tertiary care. Two nine-bed coro-
nary care units (CCUs) that consist of one bed in
each private room are located next door to each
other, and the staff of these two CCUs share com-
mon spaces for meeting, eating and resting (the
clean area). The compliance rates of hand hy-
giene in the two CCUs monitored by infection con-
trol nurses in January 2007 were 95% and 88%,
respectively. Compliance of contact isolation for
patients with multidrug-resistant organism coloni-
zation or infection reached 100% before this inves-
tigation, according to an internal audit system.
Outbreak investigation
On March 12, 2007, a CCU nurse reported to the
Head Nurse that she had fever on March 2 and a
rash developed on March 9. The Head Nurse re-
called that since February 2007, two other CCU
members had similar discomforts. She reported to
the hospital infection control team immediately.
Infectious disease physicians visited the units and
they suspected parvovirus as the potential caus-
ative agent. Outbreaks due to parvovirus in the
community or hospital had not been previously
recognized in Taiwan. Infection control measures
were re-enforced. Particular attention was paid to
hand hygiene and environmental cleaning.4,5 Staff
with fever and/or rash were put on sick leave. An
outbreak investigation was initiated.
Active surveillance was conducted in the CCUs
from March 12 to April 12, 2007 (two incubation
periods after identification of the last case). All
staff and patients who stayed in the CCUs during
the study period were surveyed for any symptoms
of fever, rash and arthralgia. Infection control
nurses also performed case-finding with daily
rounds in all hospital units as part of a hospital-
wide, nosocomial infection surveillance program.
A case was defined clinically as occurring in a
CCU patient or staff member with new onset of
fever or rash.
We derived a targeted questionnaire to identify
the source and factors that contributed to acquisi-
tion of infection. The detailed daily exposure his-
tory of each staff member between February 14
and March 14, 2007, was collected. Other infor-
mation in the questionnaire included: age and
sex; travel within the past 3 months; contact with
family, friends or patients with fever or rash; pets;
work areas; and day, time, and characteristics of
duty. The following data were collected for pa-
tients: age and sex; underlying diseases or condi-
tions; and symptoms suggestive of parvovirus
infection (fever, rash and arthralgia).
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Detection of anti-B19 IgG and IgM antibodies
One or more serum samples were collected from
all staff and patients in the CCUs during investi-
gation. The first serum sample was collected dur-
ing March 13–19, 2007. The second serum sample
was collected 2 weeks later if virological data were
equivocal or the staff themselves asked for follow-
up. Sera were tested for the presence of B19 anti-
bodies by immunoblotting. B19 antigen was made
in-house by inserting the VP1 unique gene into
the protein expression vector pThioHis A (His-
Patch ThioFusion Expression System; Invitrogen,
Carlsbad, CA, USA). The thioredoxin–VP1 fusion
protein was overexpressed and purified according
to the manufacturer’s instructions. For immuno-
blotting, the VP1 fusion protein was separated
by 10% sodium dodecyl sulfate-polyacrylamide
gel electrophoresis and blotted onto nitrocellu-
lose membranes. Sera were diluted 1:100 in 2%
skimmed milk in phosphate-buffered saline and
incubated with nitrocellulose strips overnight at
room temperature. After washing with phosphate-
buffered saline that contained 0.05% Tween-
20, the strips were incubated with peroxidase-
conjugated, goat anti-human IgG or IgM (Cappel,
West Chester, PA, USA) at room temperature for
2 hours. The conjugate was then washed off and
4-chloro-1-naphthol was used as the substrate to
make the reaction band visible.
Subjects who tested positive for IgG antibody
with negative IgM antibody were considered to
have been infected before the outbreak and clas-
sified as immune to parvovirus B19. Subjects
who tested positive for both IgM and viral DNA
were considered to have an acute infection. The
attack rate was defined as the cumulative inci-
dence of acute infection in staff and patients
evaluated between March 12 and April 12, 2007.
Detection of parvovirus B19 DNA and
nucleotide sequence of the isolates
All the sera were screened for parvovirus B19 DNA
to detect very early infection when seroconversion
had not occurred as well as the late convalescent
stage when IgM antibodies had disappeared.1,2
Viral DNA was extracted from 200 μL serum by
using the High Pure Viral Nucleic Acid Kit (Roche,
Mannheim, Germany). Nested polymerase chain
reaction (PCR) was carried out as described pre-
viously.7 The primers used to detect viremia were
set 1 (Table 1, position is numbered according to
Au isolate11). When viremia was detected, the nu-
cleotide sequences of parvovirus B19 isolates were
further analyzed. The gene from nucleotides 398–
3393 was amplified by using primer sets 2–5. The
PCR products were purified by using the QIAquick
PCR Purification Kit (Qiagen, Hilden, Germany)
and sequenced by the DyeDeoxy Terminator Cycle
Sequencing Kit (Applied Biosystems, CA, USA).
Data analysis
Clinical information and demographic data were
collected by the infection control nurses using a
standardized case–record form. Statistical analyses
were performed using SPSS version 13 (SPSS Inc.,
Chicago, IL, USA). Categorical data were analyzed
using Pearson’s χ2 test or Fisher’s exact test. Con-
tinuous data were compared using Student’s t test
or Mann–Whitney U test according to data distri-
bution. All comparisons were two-sided and a
p ≤ 0.05 was considered significant.
Results
Study population
From February 14 to March 15, 2007, 30 and 21
patients were admitted to the two CCUs and the
bed occupancy rates were 98% and 100%, respec-
tively. The mean duration of CCU stay was 5.4 days
and 7.9 days, respectively. The majority of patients
had severe cardiac diseases and the average scores
of severity were 23% and 29%, respectively, for
acute myocardial infarction Killip class III and IV;
80% and 84%, respectively, for angina Canadian
Cardiovascular Society class IV; and 79% and 84%,
respectively, for congestive heart failure New York
Heart Association class III and IV.
A total of 72 persons were in the study cohort.
This included 43 nurses, five physicians, nine other
staff and 15 patients in the CCUs. The majority
of staff were female (94.7%) and three physicians
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were male. Five of 15 patients (33.3%) were female.
On average, staffs were younger than patients with
a mean age (± standard deviation) of 34.8 ± 8.0
years and 62.9±19.2 years, respectively (p<0.001).
Four nurses (aged 28 years, 31 years, 31 years and
32 years, respectively) were pregnant (10 weeks,
26 weeks, 29 weeks and 31 weeks, respectively).
During the study period, five nurses met the
clinical case definition (cases 1–5 in Table 2).
The last case was identified on March 15, 2007.
Three of the nurses had virological evidence of
acute parvovirus infection (cases 1–3). All three
had diffuse erythematous macular rash. Part of the
rash showed a reticulated or lacy pattern on the
trunk and extremities. Case 3 had a characteristic
facial flushing (“slapped cheek” appearance).
Case 2 had reappearance of the rash 2 weeks
later. Two nurses had fever (cases 2 and 3), and
two had severe polyarthralgia (cases 1 and 3)
over both hands and ankles.
Infection control measures
Through targeted survey, we did not find any pa-
tient as the source of infection. Thus, we raised the
tentative hypothesis that this cluster of infection
occurred through propagated transmission from
case 2 through close contact with other staff, and
case 2 was possibly infected in the community. We
re-enforced hand hygiene with soap and water or
alcohol-based hand hygiene solution, wearing sur-
gical masks, and thorough disinfection using 1:50
dilution of sodium hypochlorite for healthcare
Table 1. Primers used for nested polymerase chain reaction and sequencing
Primer Position* Sequence (5–3)
Nested PCR
Set 1 outer forward nt 1855–1876 CACTATGAAAACTGGGCAATAAA
reverse nt 2097–2074 AATGATTCTCCTGAACTGGTC
inner forward nt 1872–1898 ATAAACTACACTTTTGATTTCCCTGG
reverse nt 2090–2071 TCTCCTGAACTGGTCCCGGG
Set 2 outer forward nt 391–412 TGTGAGCTAACTAACAGGTATT
reverse nt 1191–1172 ACTTCCACTGTGCCTACTGC
inner forward nt 398–422 CAGTTACAAGGTGATAAAGTAC
reverse nt 1187–1168 CCACTGTGCCTACTGCTTAG
Set 3 outer forward nt 718–737 AACCTCACAGTGTGTGTAGA
reverse nt 2097–2074 AATGATTCTCCTGAACTGGTC
inner forward nt 722–740 TCACAGTGTGTGTAGAGGG
reverse nt 2090–2071 TCTCCTGAACTGGTCCCGGG
Set 4 outer forward nt 1855–1876 CACTATGAAAACTGGGCAATAAA
reverse nt 2518–2499 ATTCCACAAATTGCTGATACAC
inner forward nt 1872–1898 ATAAACTACACTTTTGATTTCCCTGG
reverse nt 2510–2490 AATTGCTGATACACAGCTTTAG
Set 5 outer forward nt 2170–2185 CAGTTTCGTGAACTGTTAGT
reverse nt 3480–3458 AAAGCATCAGGAGCTATACTTCC
inner forward nt 2182–2198 CGTGAACTGTTAGTTGGGGTTGA
reverse nt 3393–3372 AAATATCTCCATGGGGTTGAGT
Sequencing nt 398–422 CAGTTACAAGGTGATAAAGTAC
nt 722–740 TCACAGTGTGTGTAGAGGG
nt 1137–1158 GAAACTAGTTGACTTTAACCA
nt 2090–2071 TCTCCTGAACTGGTCCCGGG
nt 1872–1898 ATAAACTACACTTTTGATTTCCCTGG
nt 2346–2369 GGTGCGATGTAGCTGCCATGTGGG
nt 3393–3372 AAATATCTCCATGGGGTTGAGT
*Position is numbered according to Au isolate.11 nt = nucleotide.
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and clean areas. Since the beginning of the out-
break investigation (March 12) until the end of
August 31, 2007, there were no more cases iden-
tified in the CCUs. A hospital-wide, nosocomial
infection surveillance program also did not iden-
tify other clusters of fever or rash among hospital
staff or patients at this hospital, from March 16
to August 31, 2007.
B19 seroprevalence and attack rate
A total of 81 sera were collected from 72 persons
evaluated. That is, a follow-up serum sample was
collected from nine persons. Overall, 23 of 72 per-
sons (31.9%) were positive for IgG. Fifteen of 
57 staff (26.3%) were seropositive and eight of
15 patients (53.3%) were seropositive (p= 0.049).
On average, 23 seropositive persons were older
than 49 seronegative persons with a mean age
(± standard deviation) of 46.1 ± 20.9 years and
38.1 ± 12.0, respectively (p = 0.045). Only one of
four pregnant nurses was seropositive (case 5).
Virological evidence of acute parvovirus infec-
tion was found in three nurses by demonstration
of viral DNA and specific IgM antibody, and they
had symptoms as described in Table 2 (cases 1–3).
All 15 CCU patients were negative for IgM and
viral DNA. Thus, the attack rate was 5.3% (3/57)
for staff and zero for patients.
Case 5 had clinical symptoms compatible with
those of parvovirus infection. She was positive for
IgG but negative for IgM and viral DNA. Therefore,
acute parvovirus B19 infection was not likely. 
A 52-year-old female cleaner (case 6) was found
to have viremia. She tested negative for IgM and
had only weak IgG anti-VP1 reaction by immuno-
blotting. This finding suggested chronic infection,
based on the weak neutralizing antibody response
to the VP1 unique domain, which can result in
inefficient viral clearance.12 The importance of an
immune response to VP1 for protective immunity
has been confirmed in animal experiments using
recombinant capsids.13
Analysis of B19 nucleotide sequence
In comparison with the reference sequence Au,11
partial nucleotide sequences (480–3355) of par-
vovirus B19 isolates from three nurses (cases 1–3)
are shown according to the position of the nu-
cleotide substitution (Table 3). In addition, the
sequences of two clinical isolates that were col-
lected during the study period (isolates 80 and
823) are listed for comparison. Isolate 80 was col-
lected from a friend of case 3, a 28-year-old man
who was hospitalized with fever, rash, and severe
polyarthralgia. Isolate 823 was obtained from a
patient with symptoms compatible with acute
Table 2. Demographic and clinical features of five cases with fever, rash or both (3 had acute parvovirus
infection) and one asymptomatic person with chronic parvovirus infection
Acute Age 
Travel or 
Case parvovirus (yr)/ Symptoms (date of onset, 2007)
exposure history
DNA IgM IgG
infection sex
1 + 31/F Rash on extremities (Feb 24), Dog + + +
severe polyarthralgia (house-hold pet)
2 + 31/F Fever (Feb 18) and then rash for 5 d, Travel, monkey + + +
reappearance of the rash (Mar 5) in the zoo
3 + 31/F Fever (Mar 2), a facial rash (slapped No + + +
cheek appearance) (Mar 8), swelling 
of extremities, severe polyarthralgia
4 − 32/F Fever and rash on extremities (Mar 14) Kid had fever − − −
5 − 31/F Rash on extremities (Mar 15) No − − +
6 − 50/F Nil No + − +
(weak)
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Table 3. Partial nucleotide sequences of the parvovirus B19 isolates from study population are shown by
nucleotide substitutions in comparison with Au reference isolate.11 Isolate 80 was collected from 
a friend of case 3. Isolate 823 was collected from a patient who visited the clinic during the study.
Nucleotide changes as compared with isolate 1 are marked as .
Reference
Study population
Clinical Clinical
Nucleotide Case 1 Case 2 Case 3Au11
Isolate 48 Isolate 2 Isolate 1
Isolate 80 Isolate 823
480 A G G G G G
554 C G G G G
558 C T T T T T
576 C T T T T T
692 C T T T T T
723 T C C C C C
726 A T T T T T
787 C T T T T T
911 G C C C C C
1022 G A A A
1068 G A A A A A
1104 G A A A A A
1269 T C C C C C
1326 T C C C C C
1332 A A A A
1365 G C C C C
1392 T C C C C C
1395 G A A A A A
1428 T C C C C C
1488 T G G G G G
1530 A G G G G G
1537 T C C C C C
1707 G A A A
2011 T C C C C C
2096 T C C C C C
2235 T C C C C C
2268 G C C C C C
2301 G A A A A A
2352 A G G G G G
2397 C T T T
2416 C T T T T T
2453 A G G G G G
2539 A T T T T T
2603 G G G G G
2608 C T T T T T
2666 G G G G G
2768 G G G G G
2947 T C C C C C
3172 G A A A A A
3182 T C C C C C
3187 C T T T T T
3223 T C C C C C
3265 A T T T T T
3307 G A A A A A
3334 G A A A A A
3355 C T T T T T
A
A/G
A
CC
GG
T
GG
GG
C
C
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parvovirus B19 infection who visited our outpa-
tient clinic and served as a community isolate.
Isolate 1 (collected from case 3 on March 13,
2007) and isolate 80 (collected from the friend
of case 3 on April 6, 2007) had identical nucleo-
tide sequences, which was concordant with mutual
transmission. Isolates with identical nucleotide
sequences have been reported in household-
acquired parvovirus B19 infection and nosocomial
outbreaks.8,14 However, isolates collected from
cases 1–3 had 2–6 nucleotide variations between
each other and had great similarity with commu-
nity isolate 823. These findings were in accor-
dance with a community outbreak14 and did not
support the hypothesis that transmission was
propagated by a single strain that occurred in the
CCUs within a short period of time.
Notably, isolate 14 (not listed in Table 3) that
was collected from case 6 had 45 nucleotide vari-
ations in comparison with isolate 1. This patient
was clearly not infected by the current endemic
parvovirus B19 strain; a finding that is compati-
ble with the speculation of chronic persistent
parvovirus B19 infection.7,15,16
Discussion
This study identified a cluster of parvovirus B19
infections in two CCUs at a teaching hospital.
We initially suspected transmission of viral infec-
tion from case 2 through close contact with other
staff. However, molecular epidemiology revealed
that three isolates collected from three nurses
with symptomatic acute infection had several
nucleotide variations and suggested an endemic
infection caused by multiple circulating strains
rather than an outbreak caused by a single strain.
We also identified a case of chronic infection
caused by an epidemiologically unrelated isolate.
The only one clonal spread was identified in a
nurse with symptomatic acute infection and in her
boyfriend. Two isolates were identical although
collected 3 weeks apart. None of the CCU patients
were infected during the study period; mainly
because staff had high compliance with wearing
surgical masks during bedside care, and hand 
hygiene before and after contact with patients 
in these units.
The seroprevalence rate defined during this
outbreak investigation was compatible with those
described in an early epidemiological study in
Taiwan.6 The seroprevalence rate was 23.5% for
those aged 20–29 years, 36% for those aged 30–
39 years, and 51.3% for those aged ≥ 60 years in
1989.6 The relatively low prevalence rates in Taiwan
were similar to those observed in Japan17,18 and
Hong Kong.8,19 By contrast, a higher prevalence
rate of > 50% has been noted in the Americas,20–22
Europe,23–26 Australia27 and Papua New Guinea.28
Transmission of parvovirus B19 to staff from
infected patients appears to be rare but has been
reported.4,5,9 It is anticipated that parvovirus might
be introduced into hospitals via infected patients,
visitors and staff if infection is epidemic in the
community.29 People with chronic infection can
remain infectious for prolonged periods.1–3,8 En-
vironmental contamination also occurs, particu-
larly following the birth of an infected infant.10
Thus, particular attention should be paid to par-
vovirus with regard to patient safety and occupa-
tional health.
Transmission of parvovirus B19 is thought to
occur following close contact during the period
of maximum infectivity (7 days before the ap-
pearance of the rash) and via large droplets or
fomites.3–5 Thus, outbreak investigation might fail
to identify the index case.30 However, B19 viral
load can reach 1010–1014 genome copies/mL dur-
ing acute infection, and low levels of parvovirus
B19 DNA might be detectable in serum for > 4
months after acute infection.31–33 Therefore, the
possibility of undetected acute infection can be
excluded in the present study. Overall, the trans-
missibility of parvovirus is low, with the most sig-
nificant risk factor in the community being contact
with school-age children.4,5,34 The annual sero-
conversion rate in elementary school employees
is around 5%, compared with 0.5% in hospital
employees even during epidemic years,34 which
varies because of differences in the level of viremia,
density of population, closeness of interaction
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and compliance with hand hygiene and environ-
mental cleaning.22,35 Attack rates between 0%
and 47% have been reported in susceptible hos-
pital staff.9,34–36 However, the high rates might
be an overestimate due to possible acquisition of
the infection in the community.4,5,8,10,29
In conclusion, the present study identified an
endemic infection caused by three circulating
strains and staff with chronic viremia. The inves-
tigation did not support the hypothesis of transmis-
sion of a single strain in CCUs. It was identified
because of alertness of hospital staff, prompt and
efficient intervention supported by infection con-
trol personnel, and an integrated expert support-
ing system. The facts that cross transmission did
not occur between staff and patients and that 
the attack rate was low might be due to partial
herd immunity and infection control precautions
adopted during the study period. Identification
and control of epidemiologically important con-
tagious diseases in the healthcare setting are im-
portant in daily practice and are a prerequisite for
healthcare settings to combat highly contagious
emerging infectious diseases or those with high
morbidity/mortality.37–40
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